Root of Nature R-Alpha Lipoic Acid 600mg Review 2026: We Checked the Clinical Evidence

Independent consumer review 

If you have been searching online for help with burning feet, tingling, numbness or diabetic peripheral neuropathy, you may have encountered advertisements for Root of Nature R-Alpha Lipoic Acid 600mg.

The advertising looks unusually scientific for a supplement.

It discusses clinical trials, R-alpha-lipoic acid, the 600mg dose used in neuropathy research and a proprietary delivery system called RootCap™. It also presents alpha-lipoic acid as a very different proposition from many poorly supported nerve supplements sold online.

There is an important reason this marketing sounds convincing:

Alpha-lipoic acid genuinely has been investigated in human clinical trials for diabetic peripheral neuropathy.

So our concern with Root of Nature is not that its principal ingredient has no evidence.

The more important question is:

Were the clinical studies being used to support the marketing actually conducted on Root of Nature R-ALA?

We investigated that question.

What we found changes how we think consumers should interpret the advertising.

The landmark studies provide legitimate evidence for alpha-lipoic acid, particularly around 600mg daily.

But they do not establish that the finished Root of Nature product itself was clinically tested.

In one of the most important long-term trials, NATHAN 1, the published research specifically identifies the product used as Thioctacid HR 600mg manufactured by MEDA Pharma.

It was not Root of Nature.

That distinction between evidence for an ingredient and evidence for a commercial finished product is central to how Brighton Savoy reviews supplements.

You can read more about our approach in Why We Write Independent Reviews of Diabetes Supplements.

Why Brighton Savoy Investigates Products Like Root of Nature

You may reasonably wonder why Brighton Savoy publishes investigations into supplements marketed for diabetes and neuropathy.

There is a simple reason.

People looking for health products are not always shopping in the same way they might shop for a television, suitcase or household appliance.

Someone searching for help with burning feet, nerve pain or numbness may have been uncomfortable for months or years. They may be worried about what their symptoms mean, may already be managing diabetes or another health condition, and understandably may very much want something to work.

At the same time, increasingly sophisticated supplement advertising reaches consumers through Facebook, Instagram, search engines, advertorials and online stores.

The advertising can contain scientific terminology, clinical-study references, testimonials, expert endorsements, before-and-after stories and explanations that make a commercial product appear closely connected with medical research.

Sometimes the underlying ingredient really does have interesting evidence.

That is exactly why careful scrutiny matters.

Brighton Savoy’s consumer research asks several basic questions:

• What does the company claim?
• What evidence actually supports those claims?
• Was the finished commercial product itself studied?
• Is the dose used in research comparable with the dose in the product?
• What can we independently verify?
• What remains uncertain?

Our objective is not to prove that every supplement is useless.

Nor is it to recommend every product containing an interesting ingredient.

It is to separate what has actually been demonstrated from what consumers may reasonably infer from the advertising.

For more information about the site’s broader editorial background, see About Brighton Savoy and our consumer research approach.

What Is Root of Nature R-Alpha Lipoic Acid?

Root of Nature sells a supplement containing 600mg of R-alpha-lipoic acid, generally shortened to R-ALA.

It is marketed particularly towards consumers experiencing symptoms commonly associated with peripheral neuropathy, including:

• burning;
• tingling;
• pins and needles;
• numbness;
• nerve discomfort; and
• altered sensation in the feet or hands.

Root of Nature emphasises several characteristics of the product, including the R form of alpha-lipoic acid, its 600mg dose, laboratory testing and its proprietary RootCap™ delivery system.

Consumers who want to examine the company’s claims themselves can view the Root of Nature promotional information here.

Importantly, alpha-lipoic acid itself is not an obscure ingredient supported only by customer testimonials.

There is genuine clinical research to examine.

What Is Alpha-Lipoic Acid?

Alpha-lipoic acid, commonly abbreviated to ALA, is a naturally occurring compound involved in cellular energy metabolism and also has antioxidant properties.

Supplemental ALA has been investigated for several potential health applications, with diabetic peripheral neuropathy being one of the most extensively researched.

Peripheral neuropathy can cause symptoms including burning, tingling, stabbing pain, numbness, altered sensitivity and reduced sensation.

For people with diabetes, reduced sensation in the feet can be particularly important because wounds, blisters or other injuries may go unnoticed.

For a broader examination of the creams, supplements and other products marketed for nerve symptoms, see our guide Diabetic Neuropathy Relief: Do Creams and Tablets Really Work?.

Does Alpha-Lipoic Acid Work for Diabetic Neuropathy?

There is reasonable evidence that alpha-lipoic acid may improve some symptoms of diabetic peripheral neuropathy.

That is very different from proving that ALA regenerates damaged nerves or reverses established neuropathy.

A 2026 systematic review and meta-analysis examined clinical research involving alpha-lipoic acid supplementation for diabetic polyneuropathy.

The researchers reported favourable findings across a number of outcomes, with benefits particularly evident for symptoms including paraesthesia, numbness and burning.

The findings were particularly interesting around 600mg per day.

However, not every measured outcome significantly improved.

The review reported uncertainty or lack of significant improvement in some measures involving long-term glucose control and objective nerve-conduction outcomes.

The appropriate interpretation is therefore that ALA may have a role as an adjunct for symptom management, rather than that it has been proven to regenerate damaged peripheral nerves.

Read the 2026 systematic review and meta-analysis on PubMed.

The SYDNEY 2 Trial: Why 600mg Matters

One of the most important oral ALA studies is the SYDNEY 2 trial.

This was a multicentre, randomised, double-blind, placebo-controlled clinical trial involving 181 people with diabetic distal symmetric polyneuropathy.

Participants received either:

• 600mg ALA daily;
• 1,200mg ALA daily;
• 1,800mg ALA daily; or
• placebo.

Treatment continued for five weeks.

Researchers measured symptoms including stabbing pain, burning pain, paraesthesia and numbness.

The Total Symptom Score decreased by approximately 51% in the 600mg group, compared with approximately 32% in the placebo group.

Higher doses did not provide a proportionately greater benefit and were associated with more adverse effects.

The researchers concluded that 600mg once daily appeared to provide the optimum risk-to-benefit ratio among the doses investigated.

Read the SYDNEY 2 study on PubMed.

This is important when assessing Root of Nature.

The company’s 600mg dosage is not simply a large number selected because it sounds impressive. There is genuine research behind that dose.

But another question remains:

Was Root of Nature the product being tested?

We Checked: Was Root of Nature Used in the Major Clinical Trials?

This became the most important part of our investigation.

A supplement company may legitimately discuss scientific research concerning an ingredient contained in its product.

But consumers can easily come away with a different impression:

“This must be the product used in those trials.”

Those are not the same thing.

The four-year NATHAN 1 trial, one of the most substantial long-term studies involving alpha-lipoic acid and diabetic neuropathy, identifies the formulation participants actually received.

The published clinical paper describes it as:

Thioctacid HR 600mg manufactured by MEDA Pharma GmbH & Co. KG.

Participants received one 600mg film-coated tablet daily or a corresponding placebo.

The NATHAN 1 trial did not test Root of Nature R-Alpha Lipoic Acid.

Read the full NATHAN 1 clinical trial.

This distinction matters.

Another supplement can contain the same headline quantity of an ingredient without necessarily being the same formulation used in the trial.

Potential differences may include:

• the chemical form of the active ingredient;
• stability;
• excipients;
• manufacturing processes;
• absorption;
• bioavailability; and
• release characteristics.

None of this proves that Root of Nature does not work.

It means clinical results from a study of another formulation should not automatically be presented as though they were results from a trial of Root of Nature itself.

This distinction is also central to our independent diabetes supplement review methodology.

What Did the NATHAN 1 Trial Actually Find?

There is another reason the NATHAN 1 study deserves careful examination.

The trial followed people with mild-to-moderate diabetic distal symmetric sensorimotor polyneuropathy over four years.

The study’s primary composite endpoint did not show a statistically significant difference between ALA and placebo.

That does not mean the study was entirely negative.

Some secondary measures of neuropathic impairment favoured alpha-lipoic acid, and the researchers reported clinically meaningful improvements according to some measures.

The correct interpretation is therefore nuanced.

NATHAN 1 provides interesting long-term evidence concerning ALA.

It does not establish that every person taking 600mg of alpha-lipoic acid will prevent neuropathy from progressing.

And importantly for this review, it did not test Root of Nature.

Is R-Alpha Lipoic Acid Better Than Ordinary ALA?

Root of Nature specifically promotes R-alpha-lipoic acid.

Alpha-lipoic acid exists as two mirror-image molecular forms commonly referred to as:

• R-ALA; and
• S-ALA.

R-ALA is the naturally occurring form.

Many conventional synthetic alpha-lipoic acid products contain a mixture of R-ALA and S-ALA.

There are legitimate biochemical and pharmacological reasons for researchers to be interested in R-ALA.

However, this creates another potential evidentiary leap.

Evidence showing interesting properties of R-ALA does not automatically establish that:

Root of Nature R-ALA provides better clinical outcomes for neuropathy than conventional alpha-lipoic acid.

A stronger conclusion of that kind would ideally require direct comparative human clinical trials involving the relevant finished formulations.

We have not identified that level of product-specific evidence.

What About RootCap™?

Root of Nature also promotes a proprietary delivery system called RootCap™.

The concept may sound attractive.

If a formulation improves stability or changes the release characteristics of an ingredient, that could theoretically affect how the ingredient behaves.

But an independent product review has to ask a different question:

Has RootCap itself been clinically demonstrated to improve neuropathy outcomes?

We have not identified a published randomised controlled clinical trial demonstrating that RootCap produces superior neuropathy outcomes compared with conventional ALA preparations.

We also should not automatically assume that RootCap is equivalent to the formulation used in historical alpha-lipoic acid trials.

Until direct clinical evidence establishes that advantage, we would describe RootCap as a proprietary formulation feature rather than a clinically proven reason that Root of Nature produces better neuropathy outcomes.

What About the “600mg on the Label, 300mg in Your Body” Claim?

One Root of Nature advertising graphic deserves particularly careful examination.

The graphic contrasts an ordinary alpha-lipoic acid product labelled 600mg with Root of Nature R-ALA 600mg.

It presents the ordinary product alongside wording suggesting approximately “300mg actual potency” or an equivalent suggestion that 600mg on an ordinary ALA label effectively becomes only around 300mg.

Root of Nature is then presented as providing 600mg both on the label and “in your body”.

It is a simple and powerful marketing message.

But it also compresses a complicated area of pharmacology into a very simple visual comparison.

We would not repeat the 600mg-versus-300mg comparison as an established fact without appropriate comparative pharmacokinetic evidence supporting that exact claim.

The amount of a substance stated on a supplement label, its absorption, bioavailability, metabolism, concentration in blood and the amount ultimately reaching different tissues are not interchangeable concepts.

A 600mg oral dose does not ordinarily mean that 600mg of the unchanged compound simply remains “in your body”.

Likewise, differences between racemic ALA and R-ALA cannot automatically be reduced to the conclusion that one 600mg product gives a person exactly 300mg while another provides exactly 600mg systemically.

Consumers should therefore regard simplified absorption graphics as marketing claims requiring evidence, rather than as a substitute for comparative human pharmacokinetic research.

Can Alpha-Lipoic Acid Repair Damaged Nerves?

This is another area where supplement marketing requires careful language.

Research suggests ALA can improve some neuropathy symptoms.

That can be meaningful.

If someone experiences less burning, tingling or pain, symptom relief matters.

But:

Feeling fewer symptoms is not the same thing as demonstrating that damaged nerves have regenerated.

The evidence is more convincing for improvements in some subjective neuropathy symptoms than it is for proving structural nerve repair.

Some objective nerve-conduction outcomes have also remained inconclusive.

Claims involving words such as:

• repair;
• regenerate;
• reverse;
• rebuild; or
• restore damaged nerves

therefore require a substantially higher standard of evidence.

Our broader Diabetic Neuropathy Relief guide explores this issue across the rapidly growing market for neuropathy creams, tablets and supplements.

Why You Shouldn’t Self-Diagnose Neuropathy

Burning, tingling and numbness can occur with diabetes, but diabetes is not the only potential cause.

Peripheral neuropathy and similar symptoms may also be associated with:

• vitamin deficiencies;
• excessive alcohol consumption;
• some medications;
• chemotherapy;
• kidney disease;
• thyroid disorders;
• autoimmune disease;
• nerve compression;
• infections; and
• other neurological conditions.

New, persistent or worsening numbness, pain, weakness or altered sensation therefore deserves appropriate medical assessment.

Taking a supplement without identifying the cause of the symptoms could potentially delay diagnosis of another underlying condition.

Can Alpha-Lipoic Acid Affect Blood Sugar?

People taking diabetes medicines should pay particular attention to this question.

ALA has been investigated in relation to glucose metabolism, but it should not be viewed as a replacement for established diabetes treatment.

Recent research has not established that taking alpha-lipoic acid produces a reliable long-term improvement in HbA1c.

People taking insulin or other glucose-lowering medication should discuss supplementation with their doctor, pharmacist or diabetes healthcare professional.

Do not reduce, discontinue or alter prescribed diabetes medication because of a supplement advertisement, customer testimonial or online review.

Alpha-Lipoic Acid Side Effects

ALA is generally considered reasonably well tolerated at commonly studied doses, but supplements are not automatically risk free.

Potential adverse effects reported in clinical research can include:

• nausea;
• vomiting;
• gastrointestinal discomfort;
• dizziness or vertigo;
• headache; and
• skin reactions.

One useful lesson from SYDNEY 2 is that more is not necessarily better.

The higher-dose groups did not provide a proportionately greater clinical benefit than 600mg, while adverse effects increased with dose.

This was one reason the researchers considered 600mg once daily to have the most favourable risk-to-benefit profile among the investigated doses.

How Root of Nature Compares With Other Neuropathy Products We’ve Reviewed

Root of Nature is particularly interesting when compared with other nerve-support products Brighton Savoy has investigated.

Our FlexiNerve independent review, for example, examined a multi-ingredient nerve supplement.

The same fundamental evidence issue arose there:

Research involving individual ingredients does not automatically prove that the finished commercial formula provides the advertised clinical outcomes.

Our Inner Dose Nerve Relief Cream review investigated a topical neuropathy product.

In that case, we separated potentially plausible temporary sensory effects from the considerably stronger proposition that a topical cream repairs or reverses underlying neuropathy.

These reviews form part of Brighton Savoy’s wider Complete Guide to Diabetes Supplements in Australia.

What We Like About Root of Nature R-ALA

1. The ingredient has legitimate research

Alpha-lipoic acid has considerably stronger human clinical evidence behind it than many ingredients promoted for nerve support.

2. The 600mg dose is meaningful

This is one of the strongest aspects of the product.

600mg corresponds with a dosage repeatedly investigated in clinical research, including SYDNEY 2.

3. The formula is relatively straightforward

A clearly identified principal active ingredient is preferable to a large proprietary blend where consumers cannot determine how much of each component they receive.

4. Laboratory testing is a positive feature

Testing relating to identity, purity and potency is preferable to asking consumers simply to trust a supplement label.

However, this distinction remains important:

Laboratory testing may help establish what is in a capsule. It does not establish that the capsule successfully treats neuropathy.

What Concerns Us About the Marketing

Our principal reservation is not that Root of Nature contains an implausible ingredient.

It does not.

The issue is what might be described as research transfer.

This happens when legitimate scientific studies involving an ingredient or another formulation are presented closely alongside a commercial product, allowing consumers to reasonably infer:

“This exact product produced those clinical results.”

That is why identifying Thioctacid HR in the NATHAN 1 paper matters.

Scientific references are useful.

But consumers deserve to know exactly what researchers actually tested.

We would like to see direct, product-specific human clinical evidence before accepting stronger claims concerning Root of Nature’s proprietary formulation, delivery technology or superiority to conventional ALA.

If meaningful product-specific clinical evidence becomes available, this review should be reassessed accordingly.

Is Root of Nature R-ALA a Scam?

Based on the evidence we reviewed, we would not describe Root of Nature R-ALA as a scam.

That would overstate the evidence.

Its principal ingredient has legitimate clinical research behind it.

The 600mg dosage is scientifically relevant.

There is evidence that oral alpha-lipoic acid may improve some symptoms of diabetic peripheral neuropathy.

Those factors distinguish Root of Nature from products based entirely on vague ingredients and customer testimonials.

Our criticism is more precise:

Consumers should not confuse clinical evidence for alpha-lipoic acid with clinical evidence for Root of Nature.

That distinction materially affects our rating.

Root of Nature R-ALA Pros and Cons

Our Root of Nature Rating

Root of Nature R-Alpha Lipoic Acid is one of the more interesting neuropathy supplements we have investigated because the scientific case for its principal ingredient is substantially stronger than it is for many competing products.

There is legitimate evidence that 600mg of oral alpha-lipoic acid may improve certain symptoms of diabetic peripheral neuropathy, particularly symptoms such as burning, tingling, numbness and paraesthesia.

That is worth acknowledging.

But our investigation also uncovered an important distinction.

The landmark clinical research consumers may encounter while researching ALA was not necessarily conducted on Root of Nature.

Most notably, the NATHAN 1 trial used Thioctacid HR 600mg manufactured by MEDA Pharma.

We have also not identified convincing independent clinical evidence demonstrating that Root of Nature’s proprietary RootCap™ delivery system produces superior neuropathy outcomes.

For those reasons, we consider Root of Nature an evidence-informed alpha-lipoic acid supplement rather than a clinically proven treatment for neuropathy.

Frequently Asked Questions

Does Root of Nature R-ALA work for neuropathy?

Alpha-lipoic acid has evidence suggesting it may improve some symptoms of diabetic peripheral neuropathy. However, we have not identified equivalent randomised clinical evidence establishing that the finished Root of Nature product itself produces those outcomes.

Was Root of Nature used in the NATHAN 1 trial?

No. The published NATHAN 1 paper identifies the formulation used as Thioctacid HR 600mg manufactured by MEDA Pharma.

Why does Root of Nature contain 600mg?

600mg is a clinically relevant dose. In the SYDNEY 2 trial, 600mg daily improved neuropathic symptoms compared with placebo and was considered to provide the most favourable risk-to-benefit ratio among the doses studied.

Does 600mg of alpha-lipoic acid repair damaged nerves?

Current evidence is stronger for improvement in certain neuropathy symptoms than it is for demonstrating structural regeneration of damaged peripheral nerves.

Is R-ALA better than ordinary alpha-lipoic acid?

R-ALA is the naturally occurring form of alpha-lipoic acid and has interesting biochemical characteristics. That does not automatically establish that every R-ALA retail product provides superior clinical outcomes compared with conventional ALA formulations.

Is RootCap clinically proven?

We have not identified published randomised controlled clinical evidence demonstrating that RootCap provides superior neuropathy outcomes compared with conventional ALA formulations.

Does 600mg on an ALA label mean 600mg is absorbed into the body?

No simple assumption like that should be made. Oral dose, absorption, bioavailability, metabolism, blood concentration and tissue exposure are different concepts. We would want to see appropriate comparative pharmacokinetic evidence before accepting a precise claim that one 600mg product provides only 300mg “in your body” while another provides the entire 600mg.

Is Root of Nature a scam?

We do not believe the available evidence justifies describing Root of Nature R-ALA as a scam. Alpha-lipoic acid is a legitimate, researched ingredient. Our concern is about separating ingredient-level clinical evidence from evidence specifically proving the Root of Nature finished product.

Where can I compare other neuropathy supplements?

Start with Brighton Savoy’s Diabetic Neuropathy Relief guide and our Complete Guide to Diabetes Supplements in Australia.

Sources and Further Reading

Brighton Savoy prefers to link directly to published research where possible so readers can examine the evidence themselves.

• SYDNEY 2 Trial – Oral alpha-lipoic acid and symptomatic diabetic polyneuropathy.
• NATHAN 1 Trial – Four-year randomised clinical trial of alpha-lipoic acid in diabetic polyneuropathy.
• 2026 systematic review and meta-analysis – Alpha-lipoic acid supplementation for diabetic polyneuropathy.
• Root of Nature marketing page – manufacturer’s promotional claims examined as part of this review.

Related Brighton Savoy Consumer Guides

• Why We Write Independent Reviews of Diabetes Supplements
• The Complete Guide to Diabetes Supplements in Australia
• Diabetic Neuropathy Relief: Do Creams and Tablets Really Work?
• FlexiNerve Independent Product Review
• Inner Dose Nerve Relief Cream Independent Review
• About Brighton Savoy and Our Consumer Research